These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22444242)

  • 1. Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial.
    Buettner F; Miah AB; Gulliford SL; Hall E; Harrington KJ; Webb S; Partridge M; Nutting CM
    Radiother Oncol; 2012 Apr; 103(1):82-7. PubMed ID: 22444242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
    Sheikh K; Lee SH; Cheng Z; Lakshminarayanan P; Peng L; Han P; McNutt TR; Quon H; Lee J
    Radiat Oncol; 2019 Jul; 14(1):131. PubMed ID: 31358029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
    Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
    Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia.
    van Dijk LV; Thor M; Steenbakkers RJHM; Apte A; Zhai TT; Borra R; Noordzij W; Estilo C; Lee N; Langendijk JA; Deasy JO; Sijtsema NM
    Radiother Oncol; 2018 Sep; 128(3):459-466. PubMed ID: 29958772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
    Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
    Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anatomical and dose changes of gross tumour volume and parotid glands for head and neck cancer patients during intensity-modulated radiotherapy: effect on the probability of xerostomia incidence.
    Marzi S; Pinnarò P; D'Alessio D; Strigari L; Bruzzaniti V; Giordano C; Giovinazzo G; Marucci L
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):e54-62. PubMed ID: 22138192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing Xerostomia by Comprehensive Protection of Salivary Glands in Intensity-Modulated Radiation Therapy with Helical Tomotherapy Technique for Head-and-Neck Cancer Patients: A Prospective Observational Study.
    Teng F; Fan W; Luo Y; Ju Z; Gong H; Ge R; Tong F; Zhang X; Ma L
    Biomed Res Int; 2019; 2019():2401743. PubMed ID: 31380414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response analysis of parotid gland function: what is the best measure of xerostomia?
    Miah AB; Gulliford SL; Clark CH; Bhide SA; Zaidi SH; Newbold KL; Harrington KJ; Nutting CM
    Radiother Oncol; 2013 Mar; 106(3):341-5. PubMed ID: 23566529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
    Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
    World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT.
    Nardone V; Tini P; Nioche C; Mazzei MA; Carfagno T; Battaglia G; Pastina P; Grassi R; Sebaste L; Pirtoli L
    Radiol Med; 2018 Jun; 123(6):415-423. PubMed ID: 29368244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional radiation dose susceptibility within the parotid gland: effects on salivary loss and recovery.
    Clark H; Hovan A; Moiseenko V; Thomas S; Wu J; Reinsberg S
    Med Phys; 2015 Apr; 42(4):2064-71. PubMed ID: 25832096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
    Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
    Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: an independent test of QUANTEC criteria using a prospectively collected dataset.
    Moiseenko V; Wu J; Hovan A; Saleh Z; Apte A; Deasy JO; Harrow S; Rabuka C; Muggli A; Thompson A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1108-14. PubMed ID: 21640505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.